Alexion Pharmaceuticals

Explore the latest insights on Alexion Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Alexion Pharmaceuticals’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

FDA Accepts Alexion's BLA for Efzimfotase Alfa With Priority Review – Potential Twice‑Monthly Enzyme Replacement Therapy for Hypophosphatasia (HPP) Patients Aged 2+
CompanyDrug

FDA Accepts Alexion’s BLA for Efzimfotase Alfa With Priority Review – Potential Twice‑Monthly Enzyme Replacement Therapy for Hypophosphatasia (HPP) Patients Aged 2+

Alexion Pharmaceuticals, a wholly‑owned subsidiary of AstraZeneca plc (NYSE: AZN), announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review…

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC

MIIT and Nine Departments Issue China's "15th Five‑Year Plan for Pharmaceutical Industry Development" – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030

MIIT and Nine Departments Issue China’s “15th Five‑Year Plan for Pharmaceutical Industry Development” – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now